These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 16342166)

  • 21. A phase II study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer.
    Villman K; Ohd JF; Lidbrink E; Malmberg L; Lindh B; Blomqvist C; Nordgren H; Bergh J; Bergström D; Ahlgren J
    Eur J Cancer; 2007 May; 43(7):1153-60. PubMed ID: 17398088
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The cisplatin, epirubicin, 5-fluorouracil, gemcitabine (PEFG) regimen in advanced biliary tract adenocarcinoma.
    Cereda S; Passoni P; Reni M; Viganò MG; Aldrighetti L; Nicoletti R; Villa E
    Cancer; 2010 May; 116(9):2208-14. PubMed ID: 20187098
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer.
    Yun J; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK
    Eur J Cancer; 2010 Mar; 46(5):885-91. PubMed ID: 20060288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
    Bamias A; Hill ME; Cunningham D; Norman AR; Ahmed FY; Webb A; Watson M; Hill AS; Nicolson MC; O'Brien ME; Evans TC; Nicolson V
    Cancer; 1996 May; 77(10):1978-85. PubMed ID: 8640659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study of short-time oxaliplatin, capecitabine and epirubicin (EXE) as first line therapy in patients with non-resectable gastric cancer.
    Dupont J; Jensen HA; Jensen BV; Pfeiffer P
    Acta Oncol; 2007; 46(3):330-5. PubMed ID: 17450468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of docetaxel, oxaliplatin and capecitabine (TEX) as first line therapy to patients with advanced gastro-oesophageal cancer.
    Andersen M; Schønnemann KR; Yilmaz M; Jensen HA; Vestermark LW; Pfeiffer P
    Acta Oncol; 2010 Nov; 49(8):1246-52. PubMed ID: 20429725
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma.
    Lee J; Im YH; Cho EY; Hong YS; Lee HR; Kim HS; Kim MJ; Kim K; Kang WK; Park K; Shim YM
    Cancer Chemother Pharmacol; 2008 Jun; 62(1):77-84. PubMed ID: 17762932
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data.
    Koo DH; Park SI; Kim YH; Kim JH; Jung HY; Lee GH; Choi KD; Song HJ; Song HY; Shin JH; Cho KJ; Yoon DH; Kim SB
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):655-63. PubMed ID: 21968953
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicentre phase I-II trial of capecitabine and oxaliplatin in combination with radiotherapy for unresectable pancreatic and biliary tract cancer: The CORGI-U study.
    Gunnlaugsson A; Anderson H; Lind P; Glimelius B; Johnsson A
    Radiother Oncol; 2010 Jun; 95(3):292-7. PubMed ID: 20451275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
    Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
    Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
    Woo IS; Moon DH; Shim BY; Lee MA; Byun JH; Kim KW; Kang JH; Choi MG; Chung IS; Hong YS; Park SY; Lee KS
    Jpn J Clin Oncol; 2005 Jan; 35(1):13-7. PubMed ID: 15681598
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trastuzumab for the treatment of HER2-positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction.
    Norman G; Rice S; Spackman E; Stirk L; Danso-Appiah A; Suh D; Palmer S; Eastwood A
    Health Technol Assess; 2011 May; 15 Suppl 1():33-42. PubMed ID: 21609651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single nucleotide polymorphisms and clinical outcome in patients with biliary tract carcinoma treated with epirubicin, cisplatin and capecitabine.
    Pacetti P; Giovannetti E; Mambrini A; Nannizzi S; Orlandi M; Tartarini R; Del Freo A; Del Tacca M; Danesi R; Cantore M
    Anticancer Res; 2009 May; 29(5):1835-40. PubMed ID: 19443413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract.
    Graham JS; Boyd K; Coxon FY; Wall LR; Eatock MM; Maughan TS; Highley M; Soulis E; Harden S; Bützberger-Zimmerli P; Evans TR
    BMC Res Notes; 2016 Mar; 9():161. PubMed ID: 26969121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gemcitabine plus cisplatin versus capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective cohort study.
    Woo SM; Lee WJ; Kim JH; Kim DH; Han SS; Park SJ; Kim TH; Lee JH; Koh YH; Hong EK
    Chemotherapy; 2013; 59(3):232-8. PubMed ID: 24356333
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
    Kim YJ; Im SA; Kim HG; Oh SY; Lee KW; Choi IS; Oh DY; Lee SH; Kim JH; Kim DW; Kim TY; Kim SW; Heo DS; Yoon YB; Bang YJ
    Ann Oncol; 2008 Jan; 19(1):99-103. PubMed ID: 17846018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Capecitabine with/without mitomycin C: results of a randomized phase II trial of second-line therapy in advanced biliary tract adenocarcinoma.
    Cereda S; Milella M; Cordio S; Leone F; Aprile G; Galiano A; Mosconi S; Vasile E; Santini D; Belli C; Auriemma A; Novarino A; Vaccaro V; Martines C; Marino D; Lutrino SE; Palazzo V; Reinach B; Aldrighetti L; Reni M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):109-14. PubMed ID: 26659366
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Assessment of the value of PEF (cisplatin, epirubicin, 5 fluorouracil) in advanced extrahepatic biliary tract and pancreatic cancer].
    Zygulska AL; Pawlega J
    Przegl Lek; 2008; 65(12):825-8. PubMed ID: 19441672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
    Ellis PA; Norman A; Hill A; O'Brien ME; Nicolson M; Hickish T; Cunningham D
    Eur J Cancer; 1995 Sep; 31A(10):1594-8. PubMed ID: 7488407
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.